US Corporate Distress Financial Stress SEC Filings — February 05, 2026

06-02-2026

Cantor Equity Partners VI, Inc. filed a Form 8-K on 2026-02-06 disclosing multiple items including Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities), Item 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item mandatory filing with no specific transaction values, financial metrics, or performance comparisons provided.

06-02-2026

Alset Inc. filed an 8-K on February 6, 2026, disclosing under Item 1.01 its entry into a material definitive agreement. Item 9.01 provides financial statements and exhibits. No specific details such as transaction value, parties involved, strategic rationale, or financial impacts are disclosed.

• ·Filing Accession Number: 0001493152-26-005416
• ·Filing size: 536 KB

06-02-2026

Nine Energy Service, Inc. filed a Form 8-K on 2026-02-06 reporting entry into a material definitive agreement under Item 1.01 and creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03. However, the filing also discloses a notice of delisting or failure to satisfy a continued listing rule or standard under Item 3.01, which signals significant compliance issues. Item 9.01 provides financial statements and exhibits, but no quantitative details such as transaction values, impacts, or metrics are disclosed.

06-02-2026

HWH International Inc. filed an 8-K on 2026-02-06 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement), Item 3.02 (Unregistered Sales of Equity Securities), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing indicating a financing-related transaction, but no specific dollar values, terms, parties, or financial impacts were disclosed. No positive or negative metrics were provided, limiting assessment of balance sheet or dilution effects.

06-02-2026

MarketAxess Holdings Inc. filed a Form 8-K on 2026-02-06 reporting multiple events under Items 1.01 (Entry into a Material Definitive Agreement), 2.02 (Results of Operations and Financial Condition), 2.03 (Creation of a Direct Financial Obligation or Off-Balance Sheet Arrangement), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). No specific transaction details, financial metrics, dollar values, percentages, or period-over-period comparisons are disclosed in the provided filing information. This multi-item filing indicates significant developments but lacks quantitative data for impact assessment.

06-02-2026

RXO, Inc. filed a multi-item Form 8-K on February 6, 2026, disclosing entry into a material definitive agreement (Item 1.01), termination of a material definitive agreement (Item 1.02), results of operations and financial condition (Item 2.02), creation of a direct financial obligation or off-balance sheet arrangement (Item 2.03), Regulation FD disclosure (Item 7.01), and financial statements/exhibits (Item 9.01). No specific transaction details, financial metrics, dollar values, or performance comparisons (positive, negative, or flat) are disclosed in the provided filing summary. Critical quantitative and qualitative details such as impacts, guidance, or scheduled events are NOT_DISCLOSED.

06-02-2026

SmartKem, Inc. filed an 8-K on February 6, 2026, reporting under Item 1.01 entry into a material definitive agreement (potentially strategic) and under Item 3.02 unregistered sales of equity securities (potentially dilutive). Item 9.01 includes financial statements and exhibits. No transaction details, sizes, financial impacts, or metrics are disclosed.

06-02-2026

SunOpta Inc. filed a Form 8-K on 2026-02-06 disclosing entry into a material definitive agreement (Item 1.01), departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers (Item 5.02), Regulation FD disclosure (Item 7.01), and financial statements and exhibits (Item 9.01). This multi-item filing signals potential strategic developments and leadership changes, but no specific transaction details, personnel names, financial metrics, dollar values, or performance comparisons (positive, negative, or flat) are disclosed. Implications remain uncertain without further details from exhibits or follow-up.

06-02-2026

Anebulo Pharmaceuticals, Inc. filed a Form 8-K on 2026-02-06 under Item 3.01 announcing a notice of delisting or failure to satisfy a continued listing rule or standard, including transfer of listing, which is a material negative event. Item 8.01 reports other events and Item 9.01 includes financial statements and exhibits, but no specific details or quantitative impacts from these items are disclosed. No positive metrics or offsets are mentioned.

06-02-2026

Vroom, Inc. filed an 8-K on 2026-02-06 reporting under Item 1.01 entry into a material definitive agreement, while also disclosing under Item 2.03 the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. This represents a multi-item filing with no specific transaction details, dollar values, or terms provided. No positive or negative financial metrics, guidance changes, or strategic context are mentioned.

• ·AccNo: 0001193125-26-040495
• ·File Size: 166 KB
• ·Sector: not specified

06-02-2026

Agape ATP Corp filed a Form 8-K on February 6, 2026 (AccNo: 0001493152-26-005471), disclosing under Item 3.03 material modifications to rights of security holders, under Item 5.03 amendments to articles of incorporation or bylaws or change in fiscal year, under Item 7.01 Regulation FD disclosure, and under Item 9.01 financial statements and exhibits. This is a multi-item filing focused on governance and disclosure matters with no quantitative financial metrics, transaction values, or performance comparisons provided in the filing summary. No positive or negative metrics are disclosed.

06-02-2026

The company filed a Form 8-K on February 6, 2026, reporting under Item 1.01 entry into a material definitive agreement and under Item 2.03 the creation of a direct financial obligation or off-balance sheet arrangement. Item 9.01 includes financial statements and exhibits. No specific transaction details, dollar values, parties, or financial impacts are disclosed in the provided filing information.

06-02-2026

Saratoga Investment Corp. filed an 8-K on 2026-02-06 reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant), along with Item 9.01 (Financial Statements and Exhibits). No specific details on the agreement, transaction size, terms, or financial impacts are disclosed in the provided filing summary. No positive or negative metrics are mentioned.

06-02-2026

Accuray Inc filed an 8-K on 2026-02-06 reporting under Item 3.01 a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, indicating a potential removal from US exchange listing. Item 9.01 discloses Financial Statements and Exhibits, but no specific financial metrics, transaction values, or delisting reasons are detailed. No positive developments or offsetting factors are mentioned.

06-02-2026

HealthLynked Corp filed an 8-K on February 6, 2026, reporting under Item 1.01 entry into a material definitive agreement, Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement, and Item 3.02 unregistered sales of equity securities, with Item 9.01 listing financial statements and exhibits. No specific transaction details, dollar values, share counts, financial metrics, or period-over-period comparisons are disclosed in the provided filing summary. The multi-item filing suggests potential dilution from equity sales and increased leverage from financial obligations, but lacks quantification.

06-02-2026

MultiSensor AI Holdings, Inc. filed a Form 8-K on 2026-02-06 under Item 1.02 announcing the termination of a material definitive agreement. No financial details, transaction size, parties involved, or impacts on operations or strategy were disclosed. This is a single-item mandatory filing representing a material event by definition.

06-02-2026

ScanTech AI Systems Inc. filed an 8-K on 2026-02-06 disclosing entry into a material definitive agreement under Item 1.01 and unregistered sales of equity securities under Item 3.02, accompanied by financial statements and exhibits under Item 9.01. No quantitative details such as transaction values, share counts, financial impacts, or strategic context are provided. This multi-item filing signals material corporate actions but lacks specifics on positive or negative implications.

06-02-2026

Grayscale Bitcoin Mini Trust ETF filed an 8-K on 2026-02-06 reporting Item 1.01 Entry into a Material Definitive Agreement, Item 8.01 Other Events, and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing disclosing a core material agreement alongside other events, but specific transaction details, parties, dollar values, financial impacts, or metrics are NOT_DISCLOSED. No quantitative data, period-over-period comparisons, guidance changes, or scheduled events are mentioned.

06-02-2026

Grayscale Ethereum Mini Trust ETF filed a Form 8-K on 2026-02-06 (AccNo: 0001193125-26-041199, Size: 1 MB) reporting under Item 1.01 entry into a Material Definitive Agreement and under Item 9.01 Financial Statements and Exhibits. This is a multi-item mandatory disclosure with no specific details provided on the agreement's parties, terms, value, financial impacts, or strategic context. No quantitative metrics, period-over-period comparisons, positive or negative performance indicators are disclosed.

06-02-2026

Vistagen Therapeutics, Inc. filed a Form 8-K on 2026-02-06 disclosing under Item 3.01 a notice of delisting or failure to satisfy a continued listing rule or standard, or transfer of listing. This represents a material negative event signaling non-compliance with exchange requirements. No quantitative financial metrics, positive developments, or additional details were disclosed.

06-02-2026

Lyra Therapeutics, Inc. filed a Form 8-K on 2026-02-06 under Item 3.01, announcing a notice of delisting or failure to satisfy a continued listing rule or standard, or transfer of listing. This represents a material negative development with no counterbalancing positive metrics disclosed. No financial details, transaction values, or operational impacts provided.

06-02-2026

Office Properties Income Trust filed an 8-K on 2026-02-06 under Items 1.01 (Entry into a Material Definitive Agreement), 1.03 (Bankruptcy or Receivership), and 9.01 (Financial Statements and Exhibits). The core event is the company's entry into bankruptcy or receivership proceedings, signaling severe financial distress with no disclosed positive offsets or mitigating factors. No quantitative details such as transaction values, financial metrics, or restructuring terms were provided.

• ·AccNo: 0001104659-26-011514
• ·File Size: 1 MB
• ·Event Date: 2026-02-06

06-02-2026

NXP Semiconductors N.V. filed a Form 8-K on February 6, 2026, reporting under Item 1.01 entry into a material definitive agreement and under Item 2.03 the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. Item 9.01 discloses financial statements and exhibits. No specific transaction details, dollar values, strategic impacts, or financial metrics are provided in the filing summary.

06-02-2026

FibroBiologics, Inc. filed a Form 8-K on 2026-02-06 (AccNo: 0001193125-26-041187) under Item 3.01 providing notice of delisting or failure to satisfy a continued listing rule or standard, or transfer of listing. No financial metrics, transaction values, guidance changes, or other quantitative details are disclosed. File size is 158 KB; sector not specified.

• ·AccNo: 0001193125-26-041187
• ·File size: 158 KB
• ·Sector: not specified

06-02-2026

GENERATION INCOME PROPERTIES, INC. filed an 8-K on 2026-02-06 (AccNo: 0001193125-26-041188, Size: 62 KB) under Item 3.01, providing notice of delisting or failure to satisfy a continued listing rule or standard; transfer of listing. No financial metrics, transaction values, guidance changes, or other quantitative details were disclosed.

06-02-2026

Commercial Vehicle Group, Inc. filed a Form 8-K on February 6, 2026, reporting under Item 1.01 entry into a material definitive agreement, under Item 5.02 departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, under Item 7.01 Regulation FD disclosure, and under Item 9.01 financial statements and exhibits. This is a multi-item filing with no specific details on the agreement, personnel changes, or disclosures provided in the available information. No quantitative financial impacts, transaction values, or other metrics are disclosed.

06-02-2026

Hennessy Capital Investment Corp. VIII filed a multi-item Form 8-K on February 6, 2026, reporting entry into a material definitive agreement (Item 1.01), unregistered sales of equity securities (Item 3.02), departure/election of directors or officers and compensatory arrangements (Item 5.02), amendments to articles of incorporation or bylaws (Item 5.03), other events (Item 8.01), and financial statements/exhibits (Item 9.01). No specific transaction details, financial metrics, dollar values, share counts, or named parties beyond the filer are disclosed. This appears to be a mandatory disclosure typical for significant corporate transactions such as potential business combinations.

06-02-2026

Karman Holdings Inc. filed a Form 8-K on February 06, 2026, reporting under Item 1.01 entry into a material definitive agreement, Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement, Item 7.01 Regulation FD disclosure, Item 8.01 other events, and Item 9.01 financial statements and exhibits. No specific details on the agreement, transaction size, financial terms, or impacts are disclosed. No quantitative metrics, period-over-period comparisons, or scheduled events are mentioned.

06-02-2026

Lexaria Bioscience Corp. filed a Form 8-K on 2026-02-06 under Item 3.01, providing notice of delisting or failure to satisfy a continued listing rule or standard, or transfer of listing. No quantitative financial metrics, transaction values, period-over-period comparisons, or other numerical data disclosed in the available information. This event indicates a material negative development with no offsetting positive metrics reported.

06-02-2026

Liberty Energy Inc. filed a multi-item Form 8-K on February 6, 2026, disclosing entry into a material definitive agreement (Item 1.01), creation of a direct financial obligation or off-balance sheet arrangement (Item 2.03), unregistered sales of equity securities (Item 3.02), other events (Item 8.01), and financial statements/exhibits (Item 9.01). No specific transaction details, dollar values, financial impacts, or quantitative metrics are disclosed in the provided filing summary. The filing appears timely as the event date matches the filing date.

06-02-2026

Netcapital Inc. filed a Form 8-K on 2026-02-06 under Accession No. 0001493152-26-005589, reporting Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. No additional financial metrics, quantitative data, transaction details, or other items are disclosed. This event indicates a failure to meet listing requirements, with no positive offsets mentioned.

06-02-2026

MANGOCEUTICALS, INC. filed an 8-K on 2026-02-06 under Item 3.01 announcing a notice of delisting or failure to satisfy a continued listing rule or standard, or transfer of listing. No financial metrics, transaction values, or additional details such as reasons for delisting, exchange involved, or impacts are disclosed. Sector is not specified.

• ·Filing Accession Number: 0001493152-26-005587
• ·Filing size: 203 KB

06-02-2026

DESTINATION XL GROUP, INC. filed an 8-K on 2026-02-06 under Item 3.01 providing notice of delisting or failure to satisfy a continued listing rule or standard, or transfer of listing. No financial metrics, transaction values, guidance changes, or other quantitative details are disclosed. No positive or offsetting developments are mentioned.

06-02-2026

Werewolf Therapeutics, Inc. filed a Form 8-K on 2026-02-06 under Item 3.01, announcing a notice of delisting or failure to satisfy a continued listing rule or standard, or transfer of listing. No financial metrics, transaction values, or additional details such as reasons for delisting, impacts, or future plans were disclosed.

• ·Accession Number: 0001193125-26-041305
• ·File Size: 144 KB
• ·Sector: not specified

06-02-2026

Aemetis, Inc. filed an 8-K on February 6, 2026 (AccNo: 0001437749-26-003382, Size: 318 KB), reporting under Item 1.01 entry into a material definitive agreement. Item 9.01 discloses financial statements and exhibits. No details on the agreement, transaction value, financial impacts, or other metrics are provided in the available information.

06-02-2026

AgEagle Aerial Systems Inc. filed an 8-K on February 6, 2026 (AccNo: 0001493152-26-005610), reporting under Item 1.01 entry into a material definitive agreement. Item 9.01 discloses financial statements and exhibits. No specific details on the agreement terms, parties, value, financial impacts, or other quantitative metrics are provided.

06-02-2026

XMax Inc. filed an 8-K on February 6, 2026 (AccNo: 0001493152-26-005624), reporting under Item 1.01 entry into a material definitive agreement. Item 9.01 discloses financial statements and exhibits. No specific details, transaction values, financial impacts, or other metrics are provided in the filing summary.

06-02-2026

Eaton Corp plc filed an 8-K on 2026-02-06 reporting entry into a material definitive agreement under Item 1.01 and creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03, with financial statements and exhibits under Item 9.01. This is a multi-item mandatory disclosure likely filed timely given the event and filing date alignment. No specific transaction details, dollar values, strategic context, or financial impacts are disclosed.

06-02-2026

Webster Financial Corp filed an 8-K on February 6, 2026, reporting under Item 1.01 entry into a Material Definitive Agreement and under Item 9.01 Financial Statements and Exhibits. No financial metrics, transaction details, positive or negative impacts, or period-over-period comparisons are disclosed. This is an informational filing with limited specifics available.

06-02-2026

Myseum, Inc. filed an 8-K on February 6, 2026, reporting under Item 1.01 entry into a material definitive agreement. Item 9.01 discloses financial statements and exhibits, likely including the agreement details. No specific transaction terms, financial metrics, positive or negative impacts, or other quantitative data are provided in the filing summary.

06-02-2026

FOXO Technologies Inc. filed a Form 8-K on February 6, 2026, disclosing under Item 1.01 entry into a material definitive agreement and under Item 3.02 unregistered sales of equity securities, with exhibits provided under Item 9.01. No details on the agreement terms, transaction size, parties involved, or financial impacts are disclosed in the provided information. This multi-item filing appears mandatory due to the triggering events.

06-02-2026

Molina Healthcare, Inc. filed an 8-K on 2026-02-06 disclosing under Item 1.01 entry into a material definitive agreement, under Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement, and under Item 2.06 material impairments. Item 9.01 provides financial statements and exhibits. The material impairments represent a negative development, while the definitive agreement could have strategic value, though details on all items are not disclosed.

06-02-2026

AB International Group Corp. filed a Form 8-K on 2026-02-06 disclosing entry into a material definitive agreement under Item 1.01, creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03, and unregistered sales of equity securities under Item 3.02, with exhibits under Item 9.01. This is a multi-item filing indicating significant corporate actions potentially involving financing or strategic transactions. No specific transaction details, dollar values, parties, impacts, or quantitative metrics are disclosed in the provided filing information.

06-02-2026

BioAtla, Inc. filed a Form 8-K on 2026-02-06 under Item 3.01 announcing a notice of delisting or failure to satisfy a continued listing rule or standard, including transfer of listing. Item 7.01 provides Regulation FD disclosure. No financial metrics, quantitative data, positive developments, or other details disclosed.

06-02-2026

Actelis Networks Inc filed an 8-K on 2026-02-06 under Item 3.01, disclosing a notice of delisting or failure to satisfy a continued listing rule or standard, and transfer of listing. No financial metrics, transaction values, or additional details such as reasons for delisting, exchange involved, or impacts were provided. Sector not specified.

06-02-2026

VisionWave Holdings, Inc. filed an 8-K on February 6, 2026, reporting entry into a material definitive agreement under Item 1.01, other events under Item 8.01, and financial statements and exhibits under Item 9.01. No specific details on the agreement, events, transaction values, financial metrics, or impacts are disclosed in the provided filing summary. No positive or negative metrics are mentioned.

• ·Multi-item 8-K filing (Items 1.01, 8.01, 9.01)
• ·AccNo: 0001731122-26-000189, Size: 257 KB
• ·Sector: NOT_DISCLOSED

06-02-2026

Catheter Precision, Inc. filed a multi-item Form 8-K on February 6, 2026, disclosing entry into a material definitive agreement (Item 1.01), unregistered sales of equity securities (Item 3.02), material modifications to rights of security holders (Item 3.03), and amendments to articles of incorporation or bylaws (Item 5.03), with exhibits under Item 9.01. These events suggest potential financing, dilution, and governance changes, but no specific transaction values, share counts, dollar amounts, or financial impacts are disclosed. No positive or negative metrics such as revenue, earnings, or balance sheet effects are mentioned.